Announcements Trials
Browse Landscape

Phase

Phase 2 13Phase 3 8Phase 1/2 4Phase 2/3 2Phase 1 2

Status

Terminated 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 5Myeloid 3Lymphoid 2Breast 2Sarcoma 1Dermatologic 1Classical hematology 1CNS 1

Conditions

Breast Neoplasms 2

Interventions

Capecitabine 17Paclitaxel 16Docetaxel 13Carboplatin 12Cyclophosphamide 11Gemcitabine 9Epirubicin 9Trastuzumab 8Letrozole 8Doxorubicin 7pertuzumab 5Cisplatin 5Vinorelbine 4130-nm albumin-bound paclitaxel 4exemestane 3Zoledronic Acid 3Tamoxifen 3Neoadjuvant Therapy 3Lapatinib 3Injections 3Drug Therapy 3Ado-Trastuzumab Emtansine 3AC protocol 3pyrotinib 2palbociclib 2camrelizumab 2apatinib 2Thiotepa 2Taxes 2Standard of Care 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2/3 × Thiotepa × Breast × Clear all
NCT01057069 2022-10-12

neo-TN

The Netherlands Cancer Institute

Phase 2/3 Active not recruiting
310 enrolled
Breast

Breast Neoplasms

NCT00448266 2021-01-22

Intensified IAA With PBPC Support in Breast Tumors With Evidence of a HRD

The Netherlands Cancer Institute

Phase 2/3 Terminated
12 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡